Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2198455 | 0.94 | EPHX1 (0.45) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL2198239 | 0.93 | — | — | |
| SCHEMBL20597382 | 0.92 | EPHX1 (0.48) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL5361321 | 0.92 | EPHX1 (0.48) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL7786789 | 0.92 | EPHX1 (0.48) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL2199616 | 0.87 | EPHX1 (0.47) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL963751 | 0.86 | — | — | |
| SCHEMBL28424604 | 0.86 | — | — | |
| SCHEMBL15822139 | 0.86 | EPHX1 (0.48) | EPHX1LMNAPOLBUSP2SMN1; SMN2 | |
| SCHEMBL10743755 | 0.84 | HPGD (0.36) | EPHX1LMNAPOLBUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20120283438-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2012-11-08 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110269781-A1 | COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2011-11-03 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| US-7977344-B2 | Compounds | GLAXOSMITHKLINE LLC (US) | 2011-07-12 | — | — | US | disclosed |
| EP-2125792-B1 | PURINE DERIVATIVES AS IMMUNOMODULATORS | GLAXOSMITHKLINE LLC (US) | 2010-12-01 | — | — | EP | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
| EP-0623127-B1 | NOVEL NEUROTRANSMITTER RELEASERS USEFUL FOR COGNITION ENHANCEMENT | DU PONT MERCK PHARMA (US) | 1997-04-02 | — | — | EP | disclosed |
| US-5532247-A | ACENAPHTHENES SUBSTITUTED IN THE 1-POSITION BY PYRIDYLMETHYL OR FLUOROPYRIDYLMETHYL; TREATING COGNITIVE OR NEUROLOGICAL DYSFUNCTION THEREWITH | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5414004-A | Cognitive activators and nervous system disorders | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-05-09 | — | — | US | disclosed |
| EP-0623127-A1 | NOVEL NEUROTRANSMITTER RELEASERS USEFUL FOR COGNITION ENHANCEMENT. | DU PONT MERCK PHARMA (US) | 1994-11-09 | — | — | EP | disclosed |
| WO-1993014085-A1 | NOVEL NEUROTRANSMITTER RELEASERS USEFUL FOR COGNITION ENHANCEMENT | THE DU PONT MERK PHARMACEUTICAL COMPANY (US) | 1993-07-22 | — | — | WO | disclosed |
| EP-0179619-B1 | HETEROCYCLIC AMIDES | ICI AMERICAS INC. (US) | 1990-09-05 | — | — | EP | disclosed |
| EP-0179619-A1 | Heterocyclic amides | ICI AMERICAS INC. (US) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283438-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | EPHX1 372/4885LMNA 4732/4885POLB 2926/4885 |
| US-20110269781-A1 | COMPOUNDS | LTC4S, LTB4R2, LTB4R | EPHX1 372/4885LMNA 4732/4885POLB 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.